-- Phase 1 clinical trial initiated (RAD204) for PDL1-positive non-small cell lung cancer and second site announced
-- Phase 1 clinical trial initiated in New York to assess 68Ga-Trivehexin's (RAD 301) efficacy in detecting lesions in patients with Pancreatic Ductal Adenocarcinoma (PDAC)
-- A$4.85m awarded under the Australian Government’s R&D tax incentive program
Sydney, Australia – 31 January 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to provide a summary of its activities for the quarter ended 31 December 2023.
For more information, download the attached PDF.
Download this document
